Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

Forward Pharma Operations ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading... Loading... Loading... Loading...

1000.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.1% 1.1%   Bankruptcy risk   2.7% 2.1% 2.2% 2.3% 4.1% 7.1% 6.2% 6.2%   Credit score (0-100)   62 69 65 63 48 33 38 38   Credit rating   BBB A BBB BBB BBB BBB BBB BBB   Credit limit (kDKK)   0.4 25.3 11.8 6.0 0.0 0.0 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   105 327 351 622 724 547 547 547   Gross profit   -27,060 -11,251 -8,158 -9,004 -7,895 -2,342 0.0 0.0   EBITDA   -27,060 -11,251 -8,158 -9,004 -7,895 -2,342 0.0 0.0   EBIT   -27,060 -11,251 -8,158 -9,004 -7,895 -2,342 0.0 0.0   Pre-tax profit (PTP)   -15,808.2 -7,546.7 -10,108.9 -9,487.0 -27,022.4 1,043.2 0.0 0.0   Net earnings   -15,791.2 -7,546.7 -10,108.9 -9,487.0 -27,022.4 1,043.2 0.0 0.0   Pre-tax profit without non-rec. items   -15,808 -7,547 -10,109 -9,487 -27,022 1,043 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Shareholders equity total   332,248 324,701 314,592 305,105 278,083 279,126 279,076 279,076   Interest-bearing liabilities   30,973 21,800 22,478 21,938 26,625 22,435 0.0 0.0   Balance sheet total (assets)   364,403 346,717 337,159 327,107 305,109 302,114 279,076 279,076   Net Debt   -311,463 -210,497 -199,539 -188,692 -179,999 -1,914 -279,076 -279,076     See the entire balance sheet 1000.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   105 327 351 622 724 547 547 547   Net sales growth   -93.6% 210.2% 7.4% 77.1% 16.5% -24.5% 0.0% 0.0%   Gross profit   -27,060 -11,251 -8,158 -9,004 -7,895 -2,342 0.0 0.0   Gross profit growth   7.1% 58.4% 27.5% -10.4% 12.3% 70.3% 0.0% 0.0%   Employees   0 0 0 0 0 0 0 0   Employee growth %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   364,403 346,717 337,159 327,107 305,109 302,114 279,076 279,076   Balance sheet change%   -43.6% -4.9% -2.8% -3.0% -6.7% -1.0% -7.6% 0.0%   Added value   -27,059.5 -11,250.6 -8,158.3 -9,004.4 -7,895.2 -2,341.6 0.0 0.0   Added value %   -25,688.0% -3,443.6% -2,324.1% -1,448.7% -1,090.5% -428.1% 0.0% 0.0%   Investments   0 0 0 0 0 0 0 0   Net sales trend   -1.0 1.0 2.0 3.0 4.0 -1.0 0.0 0.0   EBIT trend   -2.0 -3.0 -4.0 -5.0 -5.0 -5.0 0.0 0.0   1000.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   -25,688.0% -3,443.6% -2,324.1% -1,448.7% -1,090.5% -428.1% 0.0% 0.0%   EBIT %   -25,688.0% -3,443.6% -2,324.1% -1,448.7% -1,090.5% -428.1% 0.0% 0.0%   EBIT to gross profit (%)   100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 0.0% 0.0%   Net Earnings %   -14,990.8% -2,309.9% -2,879.8% -1,526.3% -3,732.3% 190.7% 0.0% 0.0%   Profit before depreciation and extraordinary items %   -14,990.8% -2,309.9% -2,879.8% -1,526.3% -3,732.3% 190.7% 0.0% 0.0%   Pre tax profit less extraordinaries %   -15,007.0% -2,309.9% -2,879.8% -1,526.3% -3,732.3% 190.7% 0.0% 0.0%   ROA %   -3.0% -2.0% -2.1% -2.3% -8.3% 0.5% 0.0% 0.0%   ROI %   -3.0% -2.0% -2.1% -2.3% -8.3% 0.5% 0.0% 0.0%   ROE %   -3.2% -2.3% -3.2% -3.1% -9.3% 0.4% 0.0% 0.0%   1000.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   91.2% 93.7% 93.3% 93.3% 91.1% 92.4% 100.0% 100.0%   Relative indebtedness %   30,525.1% 6,738.7% 6,428.9% 3,539.7% 3,732.7% 4,202.9% 0.0% 0.0%   Relative net indebtedness %   -294,555.2% -64,363.5% -56,819.4% -30,347.7% -24,805.7% -248.9% -51,023.9% -51,023.9%   Net int. bear. debt to EBITDA, %   1,151.0% 1,871.0% 2,445.8% 2,095.6% 2,279.8% 81.7% 0.0% 0.0%   Gearing %   9.3% 6.7% 7.1% 7.2% 9.6% 8.0% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   3.5% 1.8% 13.6% 7.7% 2.8% 1.8% 0.0% 0.0%   1000.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   10.7 14.9 14.1 14.0 11.3 13.1 0.0 0.0   Current Ratio   10.7 14.9 14.1 14.0 11.3 13.1 0.0 0.0   Cash and cash equivalent   342,436.3 232,297.3 222,016.5 210,630.1 206,623.9 24,348.8 0.0 0.0   1000.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   15.9 4.8 1.3 1.0 17.0 69.9 0.0 0.0   Current assets / Net sales %   327,551.1% 100,194.3% 90,509.1% 49,499.4% 42,135.5% 55,235.9% 51,023.9% 51,023.9%   Net working capital   312,884.2 305,327.9 295,142.0 285,666.5 278,043.6 279,126.1 0.0 0.0   Net working capital %   297,026.0% 93,455.6% 84,080.3% 45,959.7% 38,402.8% 51,033.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   0 0 0 0 0 0 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   0 0 0 0 0 0 0 0   EBIT / employee   0 0 0 0 0 0 0 0   Net earnings / employee   0 0 0 0 0 0 0 0